Gene · 22925
Papers2,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Donor-derived PLA2R-positive membranous nephropathy after post-mortal kidney transplantation. | Clin Kidney J | 2025 | 41220895 | PubTator, text mining | PubMed |
| Clinical study of PLA2R epitope spreading for predicting proteinuria remission in primary membranous nephropathy. | Front Immunol | 2025 | 41200161 | PubTator, text mining | PubMed |
| TIMP4 as a Potential Complementary Biomarker and Therapeutic Target in Membranous Nephropathy: A Multi-Omics Investigation with Clinical Validation. | J Inflamm Res | 2025 | 41169458 | PubTator, text mining | PubMed |
| A Rare Case of Concomitant Fibrillary Glomerulonephritis and Membranous Nephropathy in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy. | Cureus | 2025 | 41122586 | PubTator, text mining | PubMed |
| "Voclosporin in late onset lupus nephritis with anti-PLA2R antibodies". | Semin Arthritis Rheum | 2025 | 41075384 | PubTator, text mining | PubMed |
| Retrospective analysis of serum NELL-1 and EXT1/2: no significant predictive value for treatment response in a cohort of membranous nephropathy patients. | Ren Fail | 2025 | 41052965 | PubTator, text mining | PubMed |
| B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China. | Front Immunol | 2025 | 41041325 | PubTator, text mining | PubMed |
| Time-resolved fluoroimmunoassay improves sensitivity in the diagnosis of primary membranous nephropathy with low phospholipase A2 receptor antibody titer. | Sci Rep | 2025 | 41038957 | PubTator, text mining | PubMed |
| Patient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice. | Kidney Int | 2025 | 41033458 | PubTator, text mining | PubMed |
Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies). | Semin Arthritis Rheum | 2025 | 41027045 | PubTator, text mining | PubMed |
| Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management. | Front Immunol | 2025 | 41019074 | PubTator, text mining | PubMed |
| Recurrence of Glomerular Diseases (GN) After Kidney Transplantation: A Narrative Review. | J Clin Med | 2025 | 41010890 | PubTator, text mining | PubMed |
| Transcriptomic profiling of mink spleen infected by Aleutian mink disease virus: Insight into immune response. | Res Vet Sci | 2025 | 41005216 | PubTator, text mining | PubMed |
Neural epidermal growth factor-like 1 expression predicts end-stage renal disease in phospholipase A2 receptor-negative membranous nephropathy: A retrospective cohort stratified by systemic lupus erythematosus. | J Int Med Res | 2025 | 40997853 | PubTator, text mining | PubMed |
| Single-Nucleus RNA-Sequencing Identifies a Differential Profibrotic Response in Parietal Epithelial Cells in Primary Versus Maladaptive Focal Segmental Glomerulosclerosis. | Kidney Int Rep | 2025 | 40980643 | PubTator, text mining | PubMed |
| Clinical and pathological characteristics of NELL-1-positive membranous nephropathy: a case series study. | Front Med (Lausanne) | 2025 | 40978725 | PubTator, text mining | PubMed |
| CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. | Nephrology (Carlton) | 2025 | 40955731 | PubTator, text mining | PubMed |
| The Presence of Risk and Protective HLA-DQ Haplotype Combinations and PLA2R1 Risk SNP in Hungarian Patients with Membranous Nephropathy. | Int J Mol Sci | 2025 | 40943538 | PubTator, text mining | PubMed |
| Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study. | Front Immunol | 2025 | 40918120 | PubTator, text mining | PubMed |
| Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study. | Ren Fail | 2025 | 40916366 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22925/papers?page=9